Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status.

Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA, Mathis CA, Shaw LM, Trojanowski JQ, Soares H, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Jan;10(1):e9-e18. doi: 10.1016/j.jalz.2013.01.007. Epub 2013 Mar 26.

2.

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.

Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L.

Dement Geriatr Cogn Disord. 2010;29(3):204-12. doi: 10.1159/000281832. Epub 2010 Mar 20.

PMID:
20332638
3.

Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS.

Neurobiol Aging. 2015 Aug;36(8):2333-9. doi: 10.1016/j.neurobiolaging.2015.04.001. Epub 2015 Apr 4.

4.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
5.

Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.

Seo EH, Kim SH, Park SH, Kang SH, Choo IH; Alzheimer's Disease Neuroimaging Initiative.

J Korean Med Sci. 2016 Feb;31(2):286-95. doi: 10.3346/jkms.2016.31.2.286. Epub 2016 Jan 13.

6.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
7.

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.

Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC.

Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11.

8.

Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.

Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN; AIBL Research Group.

Mol Psychiatry. 2014 Jan;19(1):69-75. doi: 10.1038/mp.2012.147. Epub 2012 Oct 23.

PMID:
23089633
9.

Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.

Hatashita S, Yamasaki H.

PLoS One. 2013 Jun 14;8(6):e66877. doi: 10.1371/journal.pone.0066877. Print 2013.

10.

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Jun 1;74(6):650-659. doi: 10.1001/jamaneurol.2016.5349.

PMID:
28319241
11.

Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype.

Nadkarni NK, Perera S, Snitz BE, Mathis CA, Price J, Williamson JD, DeKosky ST, Klunk WE, Lopez OL.

JAMA Neurol. 2017 Jan 1;74(1):82-90. doi: 10.1001/jamaneurol.2016.3474.

12.

Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.

Park JC, Han SH, Cho HJ, Byun MS, Yi D, Choe YM, Kang S, Jung ES, Won SJ, Kim EH, Kim YK, Lee DY, Mook-Jung I.

Alzheimers Res Ther. 2017 Mar 22;9(1):20. doi: 10.1186/s13195-017-0248-8.

13.

High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.

Vijayaraghavan S, Maetzler W, Reimold M, Lithner CU, Liepelt-Scarfone I, Berg D, Darreh-Shori T.

Alzheimers Dement. 2014 Sep;10(5):530-540.e1. doi: 10.1016/j.jalz.2013.03.010. Epub 2013 Aug 24.

PMID:
23978325
14.

The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.

Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, DeCarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ.

JAMA Neurol. 2013 Apr;70(4):488-95. doi: 10.1001/2013.jamaneurol.405.

15.

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.

J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.

PMID:
25649653
16.

APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.

Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Lowe VJ, Jack CR Jr, Whitwell JL.

Alzheimers Dement. 2014 Nov;10(6):630-6. doi: 10.1016/j.jalz.2014.03.004. Epub 2014 Jun 28.

17.

Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative.

Toledo JB, Toledo E, Weiner MW, Jack CR Jr, Jagust W, Lee VM, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Nov;8(6):483-9. doi: 10.1016/j.jalz.2011.08.008.

18.

Beta-amyloid associated differential effects of APOE ε4 on brain metabolism in cognitively normal elderly.

Yi D, Lee DY, Sohn BK, Choe YM, Seo EH, Byun MS, Woo JI.

Am J Geriatr Psychiatry. 2014 Oct;22(10):961-70. doi: 10.1016/j.jagp.2013.12.173. Epub 2014 Jan 4.

PMID:
24495404
19.

Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.

Kim CM, Hwang J, Lee JM, Roh JH, Lee JH, Koh JY; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Curr Alzheimer Res. 2015;12(6):563-71.

PMID:
26027813
20.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175

Supplemental Content

Support Center